Suzhou Generic Medical Technology
New type of medicine that is based on personalized medicine and is developing rapidly with the advancement of genomic sequencing technology and the cross-application of bioinformatics and big data…
About Suzhou Generic Medical Technology
Regend operates in the regenerative medicine sector, focusing on the research, development, and commercialization of cell therapy and health diagnostic products. The company serves clients in the healthcare industry, including patients and medical professionals, by providing innovative solutions for lung regeneration and other medical conditions. Regend's business model revolves around building an industrial chain that encompasses basic research, pre-clinical development, clinical trials, and product commercialization. Revenue is generated through the development and sale of regenerative medicine products, supported by a robust R&D infrastructure and compliance with international quality standards. The company is committed to prioritizing the life and health of consumers and patients, leveraging scientific advancements to transform healthcare outcomes.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Feb 2026 | $48M | $193M | Hefei Hi-Tech Venture Capital · Hefei Industry Investment Group · Hongtai Fund (Shenzhen) · Tasly Capital | ↗ |
| SERIES BOther financing | Feb 2025 | $2.8M | $69M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Suzhou Generic Medical Technology is 160 monthly website visits, down 95.8% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Suzhou Generic Medical Technology in the Suzhou Shi ecosystem
The Suzhou Generic Medical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
- QMQiluo Mingyuan
- CSChina Merchants Securities
Shenzhen Qianhai Wanrong Hongtu Investment Fund
SooChow Securities- SCShenzhen Venture Capital
Series B and later4 investors entered at this stage
- HCHefei Hi-Tech Venture Capital
- HGHefei Industry Investment Group
- H(Hongtai Fund (Shenzhen)
Tasly Capital
Other known investors1 additional known investor
Tongji University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Suzhou Generic Medical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Suzhou Generic Medical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








